OBJECTIVE: To determine the safety and immunogenicity of an idiotypic anti-dsDNA vaccine in patients with nonactive systemic lupus erythematosus (SLE) and stable lupus nephritis. METHODS:Patients with SLE with a history of nephritis were randomized for vaccination with the murine anti-dsDNA monoclonal antibody (Mab) 3E10 in a dose ranging, double blind, placebo controlled study (phase I). RESULTS: Of the 9 patients injected with Mab 3E10, 5 showed a human anti-mouse antibody (HAMA) response, in large part antiidiotypic, which developed within the first 3 months in 3 strong HAMA responders, and more than one year after immunization in an initially weak HAMA responder. All but one nonresponder were receiving low dose prednisone. No adverse events, in particular no evidence of lupus flares, and no untoward laboratory findings were reported over a followup of 2 years. CONCLUSION: In patients with stable lupus nephritis, immunization with Mab 3E10 appears safe and can generate a significant antiidiotypic response. Idiotypic vaccination may be an approach to specific immunotherapy of autoimmune lupus nephritis.
RCT Entities:
OBJECTIVE: To determine the safety and immunogenicity of an idiotypic anti-dsDNA vaccine in patients with nonactive systemic lupus erythematosus (SLE) and stable lupus nephritis. METHODS:Patients with SLE with a history of nephritis were randomized for vaccination with the murine anti-dsDNA monoclonal antibody (Mab) 3E10 in a dose ranging, double blind, placebo controlled study (phase I). RESULTS: Of the 9 patients injected with Mab 3E10, 5 showed a human anti-mouse antibody (HAMA) response, in large part antiidiotypic, which developed within the first 3 months in 3 strong HAMA responders, and more than one year after immunization in an initially weak HAMA responder. All but one nonresponder were receiving low dose prednisone. No adverse events, in particular no evidence of lupus flares, and no untoward laboratory findings were reported over a followup of 2 years. CONCLUSION: In patients with stable lupus nephritis, immunization with Mab 3E10 appears safe and can generate a significant antiidiotypic response. Idiotypic vaccination may be an approach to specific immunotherapy of autoimmune lupus nephritis.
Authors: Grant L Austin; Zoe R Simmons; Jack E Klier; Alberto Rondon; Brad L Hodges; Robert Shaffer; Nadine M Aziz; Tracy R McKnight; James R Pauly; Dustin D Armstrong; Craig W Vander Kooi; Matthew S Gentry Journal: Mol Pharm Date: 2019-08-02 Impact factor: 4.939
Authors: Luis Carreño; Francisco Javier López-Longo; Carlos Manuel González; Indalecio Monteagudo Journal: Paediatr Drugs Date: 2002 Impact factor: 3.022
Authors: James E Hansen; Grace Chan; Yanfeng Liu; Denise C Hegan; Shibani Dalal; Eloise Dray; Youngho Kwon; Yuanyuan Xu; Xiaohua Xu; Elizabeth Peterson-Roth; Erik Geiger; Yilun Liu; Joseph Gera; Joann B Sweasy; Patrick Sung; Sara Rockwell; Robert N Nishimura; Richard H Weisbart; Peter M Glazer Journal: Sci Transl Med Date: 2012-10-24 Impact factor: 17.956
Authors: C Iking-Konert; S Stocks; F Weinsberg; R Engelbrecht; E Bleck; A Perniok; R Fischer-Betz; S Pincus; L Nardone; M Schneider Journal: Ann Rheum Dis Date: 2004-09 Impact factor: 19.103
Authors: Philip W Noble; Sasha Bernatsky; Ann E Clarke; David A Isenberg; Rosalind Ramsey-Goldman; James E Hansen Journal: Nat Rev Rheumatol Date: 2016-03-24 Impact factor: 20.543
Authors: Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs Journal: Hum Mol Genet Date: 2013-01-09 Impact factor: 6.150